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Global outbreak research: harmony, not hege-
mony
The ISARIC clinical characterisation group
To make clinical and biological observations in a time-frame likely to benefit
patients during disease outbreaks, coordination in global research must match
the speed of spread of novel pathogens. Time is short. Circumstances compel us
to work together, across the world, to understand, treat, and prevent COVID-19.
During previous outbreaks, clinical research has often been set up ad hoc and
conducted in silos, using different methodologies and designs. This limits oppor-
tunities to compare results, or to combine smaller studies to get answers quickly.
It is perhaps self-evident that harmonisation of clinical investigation during
outbreaks is desirable. The WHO clinical management research prioritization
group identified harmonized clinical characterization research as its first priority
for COVID-19.
Harmonisation creates opportunities for individual investigators to compare
results or collaborate, without applying burdens or obligations. Also, at least
for the authors of this article, the quality and breadth of research is improved
by collaborative development and peer review of shared protocols. For example,
in the current outbreak, a clinician might design a study to identify risk factors
for progression, co-infections, and mechanisms of critical illness. Fewer clinicians
would consider the need to obtain serum for groups with the capability to
make new assays for seroepidemiology, or peripheral blood mononuclear cells for
monoclonal antibody therapeutics. Wide collaboration leads to better, faster
science.
Achieving global coordination is difficult enough at the best of times; during a
crisis it may seem impossible. But in each new crisis, the same questions arise
again and again. So the same designs can tackle them. We believe that global
harmonisation is possible, at least in the intermittently-indispensable field of
outbreak research. To achieve it we need to make harmonized investigation
easier than establishing isolated independent studies, respect autonomy and
sovereignty of investigators, and relinquish normal routes of academic recognition
for this work.
To this end, in 2012 a single, standardized generic research protocol was created
for clinical characterization of any emerging infection (the ISARIC/WHO Clinical
Characterisation Protocol, CCP: isaric.net/ccp). This took years of interna-
tional and cross-speciality consensus-building.1 Since the fundamental research
questions in a new outbreak are predictable, the protocol can be established
and approved in “peacetime”, maintained in a hibernating state, then rapidly
implemented when required. Carefully-designed, flexible biological sampling
schedules are included in tiers according to local resources, modular additional
studies for specific situations, and scalable case report forms.1 These tools were
released under an open-source licence: anyone can download these materials and
1
use, adapt or distribute them. Clinical research feels like it is 95% about filling
in forms. We filled in some of the forms, so you don’t have to.
Figure 1: Sample schedules in use in selected countries
The CCP was implemented in Brazil in response to the emergence of Zika virus
and chikungunya virus in Latin America, facilitating studies of viral shedding
and serology.2 It was used for cohort studies of critically-ill patients with MERS.3
The Uganda Virus Research Institute is using it to study severe acute febrile
illness and severe influenza.4
The value of this approach is becoming apparent in the age of COVID-19.
The original reports on clinical findings in COVID-19 utilised harmonised data
collection.5,6 46 countries have registered to record clinical data using the ISARIC
CCP CRF and investigators in many countries are planning to use the CCP
biological sampling protocol to conduct coordinated studies of transmission,
prognostication, pathogenesis and diagnostics.
Understanding the genetic mechanisms underlying susceptibility7 may directly
advance our understanding of disease mechanisms8 and possible treatments,9 but
robust studies require very large numbers of critically ill patients. This requires
open, collegiate, global collaboration. GenOMICC (Genetics Of Mortality In
Critical Care, https://genomicc.org) is an open consortium in which clinicians
have been recruiting critically ill patients since 2016. Importantly, this work is
led by the clinicians treating the patients, in collaboration with experts in host
genetics.
2
Operating clinical trials at global scale presents many additional challenges,
but even in this domain, significant progess has been made. In advance this
catastrophe, the critical care community created a highly-efficient randomised,
embedded multifactorial adaptive platform trial for community-acquired pneu-
monia (REMAP-CAP, https://www.remapcap.org). This is a single trial,
established in 13 countries, with the capacity to test new hypotheses quickly.
Perhaps most ambitious of all, WHO has developed a global platform - the
SOLIDARITY trial - for evaluation of widely-available interventions to treat
COVID-19.
Catastrophes bring about surges in innovation and drastic social change. Within
our own community, we believe that perceptions of academic excellence have
long under-valued teamwork and collegiality. We hope our colleagues across
the world will make use of these tools, either in collaboration or independently,
to harmonise clinical research efforts and fulfil the duties of medical science to
humanity in the shortest possible time.
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